Revance Therapeutics Future Growth

Future criteria checks 5/6

Revance Therapeutics is forecast to grow earnings and revenue by 67.8% and 23.2% per annum respectively while EPS is expected to grow by 67.8% per annum.

Key information

67.8%

Earnings growth rate

67.8%

EPS growth rate

Pharmaceuticals earnings growth	22.8%
Revenue growth rate	23.2%
Future return on equity	n/a
Analyst coverage	Good
Last updated	24 Apr 2024

Recent future growth updates

Recent updates

What Revance Therapeutics, Inc.'s (NASDAQ:RVNC) 30% Share Price Gain Is Not Telling You

Mar 04

Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain

Feb 29

Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%

Dec 28

Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be

Nov 10

Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt

Aug 10

Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors

Jun 14

Earnings and Revenue Growth Forecasts

NasdaqGM:RVNC - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	505	11	46	143	9
12/31/2025	386	-90	-41	20	10
12/31/2024	282	-185	-128	-56	11
12/31/2023	234	-324	-223	-217	N/A
9/30/2023	214	-414	-210	-204	N/A
6/30/2023	186	-358	-214	-211	N/A
3/31/2023	157	-352	-204	-202	N/A
12/31/2022	133	-356	-197	-194	N/A
9/30/2022	109	-274	-214	-208	N/A
6/30/2022	99	-263	-210	-203	N/A
3/31/2022	90	-274	-216	-208	N/A
12/31/2021	78	-281	-232	-222	N/A
9/30/2021	63	-297	-247	-239	N/A
6/30/2021	47	-303	-250	-242	N/A
3/31/2021	29	-292	-218	-210	N/A
12/31/2020	15	-282	-183	-179	N/A
9/30/2020	4	-249	-152	-150	N/A
6/30/2020	0	-209	-129	-126	N/A
3/31/2020	0	-186	-141	-138	N/A
12/31/2019	0	-159	-109	-106	N/A
9/30/2019	1	-155	-108	-104	N/A
6/30/2019	3	-146	-103	-97	N/A
3/31/2019	4	-143	-112	-105	N/A
12/31/2018	4	-143	-111	-104	N/A
9/30/2018	3	-138	-107	-102	N/A
6/30/2018	1	-136	-101	-98	N/A
3/31/2018	0	-128	-89	-85	N/A
12/31/2017	0	-121	-98	-95	N/A
9/30/2017	0	-111	N/A	-80	N/A
6/30/2017	0	-99	N/A	-73	N/A
3/31/2017	0	-97	N/A	-65	N/A
12/31/2016	0	-89	N/A	-60	N/A
9/30/2016	0	-85	N/A	-63	N/A
6/30/2016	0	-86	N/A	-62	N/A
3/31/2016	0	-78	N/A	-58	N/A
12/31/2015	0	-73	N/A	-56	N/A
9/30/2015	0	-66	N/A	-48	N/A
6/30/2015	0	-60	N/A	-47	N/A
3/31/2015	0	-57	N/A	-47	N/A
12/31/2014	0	-63	N/A	-55	N/A
9/30/2014	1	-49	N/A	-60	N/A
6/30/2014	1	-48	N/A	-54	N/A
3/31/2014	1	-38	N/A	-62	N/A
12/31/2013	1	0	N/A	-48	N/A
9/30/2013	0	-10	N/A	-49	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RVNC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).

Earnings vs Market: RVNC is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: RVNC is expected to become profitable in the next 3 years.

Revenue vs Market: RVNC's revenue (23.2% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: RVNC's revenue (23.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if RVNC's Return on Equity is forecast to be high in 3 years time

Revance Therapeutics Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Forecast to breakeven in 2026

Price target decreased by 18% to US$16.33

Price target decreased by 14% to US$23.17

Price target decreased by 9.9% to US$25.67

Price target decreased by 18% to US$29.25

Price target decreased by 7.1% to US$33.67

Recent updates

Forecast to breakeven in 2026

Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting

Insufficient new directors

Revance Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

What Revance Therapeutics, Inc.'s (NASDAQ:RVNC) 30% Share Price Gain Is Not Telling You

Revance Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

Price target decreased by 18% to US$16.33

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain

Revance Therapeutics, Inc. Announces Executive Changes

Revance Therapeutics, Inc. Receives Permanent J-Code for DAXXIFY and Announces Publication of Daxify Pivotal Study (ASPEN-1) Results in Neurology

Price target decreased by 14% to US$23.17

Price target decreased by 9.9% to US$25.67

Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%

New minor risk - Profitability

Revance Therapeutics, Inc. Reports Consolidated Impairment for the Quarter Ended September 30, 2023

Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be

Price target decreased by 18% to US$29.25

Revance Therapeutics, Inc. Appoints Erica Jordan as Senior Vice President of Commercial to Chief Commercial Officer, Aesthetics

Price target decreased by 7.1% to US$33.67

Revance Therapeutics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

New minor risk - Share price stability

Price target decreased by 9.0% to US$36.25

Consensus EPS estimates fall by 13%

Senior VP notifies of intention to sell stock

U.S. FDA Approves First Therapeutic Indication for Revance's Daxxify (Daxibotulinumtoxina-Lanm) for Injection for the Treatment of Cervical Dystonia

Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

CEO & Director notifies of intention to sell stock

Revance Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

CEO & Director notifies of intention to sell stock

Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors

CEO & Director notifies of intention to sell stock

CFO & Principal Accounting Officer notifies of intention to sell stock

CEO & Director recently sold US$2.4m worth of stock

Forecast to breakeven in 2025

CEO & Director notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

CFO & Principal Accounting Officer notifies of intention to sell stock

Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

CFO & Principal Accounting Officer notifies of intention to sell stock

CEO & Director recently sold US$2.2m worth of stock

No longer forecast to breakeven

CEO & Director notifies of intention to sell stock

Consensus estimates of losses per share improve by 12%

CFO & Principal Accounting Officer notifies of intention to sell stock

Forecast to breakeven in 2025

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CFO & Principal Accounting Officer notifies of intention to sell stock

Forecast to breakeven in 2025

CFO & Principal Accounting Officer notifies of intention to sell stock

Forecast to breakeven in 2025

Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application for Daxxify (Daxibotulinumtoxina-Lanm) for Injection for the Treatment of Cervical Dystonia

Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Revance Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Revance Therapeutics, Inc. Submits Supplemental Biologics License Application (sBLA) for DAXXIFY (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

Revance Therapeutics submits sBLA for Daxxify for cervical dystonia

Revance Therapeutics, Inc. Appoints David A. Hollander as Chief Medical Officer

Revance Therapeutics, Inc. Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY (Daxibotulinumtoxina-Lanm) for Injection in the Aesthetic Surgery Journal

Senior VP notifies of intention to sell stock

Revance to Present Data from Phase 2 Juniper Clinical Trial Evaluating DAXXIFY™ (Daxibotulinumtoxina-Lanm) Injection for the Treatment of Upper Limb Spasticity At the International Congress of Parkinson and Movement Disorder Society (MDS)

Revance Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

Revance Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

Revance Therapeutics, Inc. Announces FDA Approval of DAXXIFY

Price target increased to US$31.70

Revance climbs 14% as FDA approves facial injectable for frown lines

Revance Therapeutics: More Risk To Sept. 8 PDUFA Than It Seems